|
|
 |
|
Viewing report
|
|
|
|
Back Pain Report 2008
WWMR, April 2009
Providing an Enhanced Perspective on Back Pain:
- Provides an epidemiological forecast for key types of back pain in the US market in 2008, 2013, and 2018
- Presents expert analysis of the commercial potential and key differences among products in development for the treatment of back pain
- Includes a PowerPoint presentation reporting views of Pain Specialists treating Back Pain.
- Describes the critical factors driving back pain market growth through 2018
- Insights based upon Pain Clinic Monitor, profiling back pain conditions and interviews with specialists in Pain Centers treating back pain.
A Complex Market of Diverse Needs
Back pain is one of the most common pain conditions-approximately 80% of Americans will be affected with low back pain at some point in their lifetime. Five out of ten working adults have some back pain every year. The cause of back pain is not always apparent and for approximately 90% of individuals with back pain, the specific cause cannot be identified. Most back pain goes away on its own, with or without medication, though it may take some time to do so. Almost $100 billion is spent annually to provide relief from back and neck pain through surgery, doctor's visits, X-rays, MRI scans and medications. Back pain can arise from many causes, including the bones, the ligaments that connect muscle to the bone, or the muscles that control movement. It can also arise directly or indirectly from the invertebral discs, often occurs when nerves, normally protected by the spine, are compressed.
An Opportunity to Meet Unmet Need for Therapy
By 2018, there will be approximately 100 million individuals in US suffering from some form of back pain. Given this substantial patient population, back pain has received particular attention in recent years. Treatment of back pain varies by etiology, with opioids and other narcotic agents typically prescribed for patients with more severe or chronic pain. Opioid-based medications and NSAIDs are the most commonly prescribed drug classes for back pain. SAIDs and muscle relaxants are the most commonly used medications for acute back pain. Neurologic medications, such as anticonvulsants and antidepressants, are the most common additional drug classes prescribed for back pain. Patients often develop tolerance to their drugs and thus the choice of drugs and their doses need constant re-assessment by the treating physician. There is still a great need to develop novel therapies that are safe and effective with fewer side effects than currently marketed products.
Report Objectives & Methodology
In this report, we provides an overview of the back pain in the US market.
This report also summarizes WWMR, Inc.’s current understanding of back pain mechanisms, and highlights promising targets for drug development. Also reviewed are new treatments already in development that offer the promise of improved pain management of back pain in the near future.
Models representing patient populations and the commercial value (USD) of this market in 2008, 2013, and 2018 are presented.
Expert analysis and commentary describing the future back pain market
are based on:
- Pain Clinic Monitor, profiling back pain (100 Pain Clinics)
- Interviews with Pain Clinicians and Primary Care Physicians
- Comprehensive analysis of drug uses for back pain, including estimations of prescription size, number of refills, and cost
- Evaluation of drugs in the pain drug pipeline, with conclusions on the future directions in the treatment of back pain
- In-depth analysis of the medical literature, including treatment review articles, medical textbooks, epidemiology studies, and clinical studies
- Thorough review of country-specific and overall trends
Market and patient population forecasts are based on a consensus developed from industry experience, clinician input, and analysis of secondary sources.
US Back Pain report will allow pharmaceutical and biotechnology executives to:
- Understand the epidemiology of back pain, including projected growth rates, by type of back pain
- Recognize the specific aspects of back pain that have high market potential in the next 10 years
- Target specific patient populations who will benefit most from drugs in the back pain pipeline
- Anticipate upcoming competitors and product licensing opportunities
- Understand the type and level of unmet need in the US back pain market
- Recognize the impact of special market dynamics, including potential off-label usage, on product uptake forecasts
US Back Pain report also includes a PowerPoint presentation which comprises perspectives form pain clinic specialists and Primary Care Physicians with expertise in treating back pain.
This presentation includes:
- A review of back pain treatment practices incorporating physician verbatims.
- Physician perspectives on routes of administration of back pain medications
- An analysis of physician satisfaction with current back pain treatments
- Physician perspectives on recent advances in back pain treatment
- An analysis of physician-reported unmet needs in back pain treatment.
Customers who bought this item also bought
Pain Therapeutics - Drugs, Markets and Companies
US Cancer Pain Report
US Neuropathic Pain 2008 - 4th Edition: Market Potential Through 2018
Stakeholder Opinions: Back Pain - Gain competitive edge by targeting subpopulations
Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
Pain Management - Evaluation and Treatment Issues, 2nd Edition (2009 update)
The Global Pain Therapeutics Market, 3rd Edition - Market Analysis, R&D Pipelines and Competitive Landscape
U.S. Neuropathic Pain Medications Markets
The Global Pain Therapeutics Market: Market Analysis, R&D Pipelines and Competitive Landscape
Peripheral Neuropathy and Neuropathic Pain
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
|
|
|
|
